anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells
X01-CN-A1
Phase 1 mab active
Quick answer
anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells for Relapsed/refractory Lymphoma is a Phase 1 program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Relapsed/refractory Lymphoma
- Phase
- Phase 1
- Modality
- mab
- Status
- active